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SciBACKGROUND Antiarrhythmic drugs are widely used to treat patients with atrial ﬁbrillation (AF), but the mechanisms
conveying their variable effectiveness are not known. Recent data suggested that paired like homeodomain-2
transcription factor (PITX2) might play an important role in regulating gene expression and electrical function of the adult
left atrium (LA).
OBJECTIVES After determining LA PITX2 expression in AF patients requiring rhythm control therapy, the authors
assessed the effects of Pitx2c on LA electrophysiology and the effect of antiarrhythmic drugs.
METHODS LA PITX2 messenger ribonucleic acid (mRNA) levels were measured in 95 patients undergoing thoracoscopic
AF ablation. The effects of ﬂecainide, a sodium (Na+)-channel blocker, and d,l-sotalol, a potassium channel blocker, were
studied in littermate mice with normal and reduced Pitx2c mRNA by electrophysiological study, optical mapping, and
patch clamp studies. PITX2-dependent mechanisms of antiarrhythmic drug action were studied in human embryonic
kidney (HEK) cells expressing human Na channels and by modeling human action potentials.
RESULTS Flecainide 1 mmol/l was more effective in suppressing atrial arrhythmias in atria with reduced Pitx2c mRNA
levels (Pitx2cþ/–). Resting membrane potential was more depolarized in Pitx2cþ/– atria, and TWIK-related acid-sensitive
Kþ channel 2 (TASK-2) gene and protein expression were decreased. This resulted in enhanced post-repolarization
refractoriness and more effective Na-channel inhibition. Deﬁned holding potentials eliminated differences in ﬂecainide’s
effects between wild-type and Pitx2cþ/– atrial cardiomyocytes. More positive holding potentials replicated the increased
effectiveness of ﬂecainide in blocking human Nav1.5 channels in HEK293 cells. Computer modeling reproduced an
enhanced effectiveness of Na-channel block when resting membrane potential was slightly depolarized.
CONCLUSIONS PITX2 mRNA modulates atrial resting membrane potential and thereby alters the effectiveness of
Na-channel blockers. PITX2 and ion channels regulating the resting membrane potential may provide novel targets for
antiarrhythmic drug development and companion therapeutics in AF. (J Am Coll Cardiol 2016;68:1881–94) © 2016 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
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AAD = antiarrhythmic drug
APD = action potential
duration
ERP = effective refractory
period
HEK = human embryonic
kidney
LA = left atrium
LAA = left atrial appendage
mRNA = messenger ribonucleic
acid
Na = sodium
PITX2 = paired like
homeodomain-2
PRR = post-repolarization
refractoriness
RMP = resting membrane
potential
SNP = single nucleotide
polymorphism
TASK-2 = TWIK-related
acid-sensitive KD channel
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1882A trial ﬁbrillation (AF) causes cardio-vascular death, frequent hospitali-zation, and cognitive decline even
in patients treated according to guidelines
(1–3). Antiarrhythmic drug (AAD) therapy re-
mains the most commonly used treatment to
maintain sinus rhythm in AF patients, but
AAD effectiveness remains limited (3). Un-
fortunately, we lack a basic understanding
of why AADs prevent AF over long periods
in some patients but not in others (4,5). Iden-
tifying factors that modify the effects of
AADs would allow the selection of respon-
sive patients and could help guide develop-
ment of novel AADs (6).
Paired like homeodomain-2 transcription
factor (PITX2) is a transcription factor that
regulates the development of the left atrium
(LA) and thoracic organs. Its c isoform is
expressed in the adult LA and regulates the
expression of LA ion channels (7–9). Low
atrial Pitx2 expression renders mice suscep-
tible to AF and shortens the LA action poten-
tial (8,10,11). In this study, we investigatedhow atrial PITX2 modiﬁes the effects of AADs.SEE PAGE 1895We detected variable LA PITX2 messenger ribonu-
cleic acid (mRNA) expression in AF patients requiring
rhythm control therapy. After ﬁnding that low Pitx2c
enhanced the effect of ﬂecainide, mediated by a more
positive resting membrane potential (RMP), we
identiﬁed reduced TWIK-related acid-sensitive Kþ
channel 2 (TASK-2) expression as a possible driver of
this effect and replicated these effects in cells
expressing human sodium (Na) channels and in a
human atrial action potential model.
METHODS
All experiments were conducted under the Animals
(Scientiﬁc Procedures) Act 1986, and approved by the
home ofﬁce (PPL number 30/2967) and the institu-
tional review board at the University of Birmingham.
Analyses of human atrial tissue were approved by theW VIDI Grant 016.146.310. Dr. Riley is currently employed by B
titutional research grant support from DFG, MRC, and Gilead Inc
erman Centre for Heart Research and from several drug and de
onoraria from several such companies. Drs. Syeda, Fabritz,
40571) held by the University of Birmingham on genotype-speciﬁ
uthors have reported that they have no relationships relevant t
s contributed equally to this work.
received February 11, 2016; revised manuscript received July 5,institutional review board of Academic Medical Cen-
ter, Amsterdam, the Netherlands. All patients pro-
vided written informed consent.
Left atrial appendages (LAAs) were excised from 95
patients undergoing bilateral thoracoscopic AF
ablation either in the AFACT (Atrial Fibrillation
Ablation and Autonomic Modulation via Thoraco-
scopic Surgery) trial (12) or undergoing similar pro-
cedures in the same centers using an endoscopic
stapling device, snap frozen in liquid nitrogen and
stored at –80C (13). Deoxyribonucleic acid and
ribonucleic acid were extracted using DNeasy
and RNeasy kits (Qiagen Ltd., Manchester, United
Kingdom), respectively. PITX2 mRNA content was
quantiﬁed by quantitative polymerase chain reaction.
Single nucleotide polymorphisms (SNPs) rs2200733,
rs6838973, and rs1448818 (14) were identiﬁed using
TaqMan assays (Thermo Fisher Scientiﬁc Inc., Wal-
tham, Massachusetts).
Adult mice (age 12 to 16 weeks) on an MF1 back-
ground with normal or reduced (Pitx2cþ/) atrial
Pitx2c expression were studied (8).
LA epicardial monophasic action potentials were
recorded from Langendorff-perfused murine hearts
(8,15). Programmed stimulation was performed at
baseline and with ﬂecainide 1 mmol/l or d,l-sotalol
10 mmol/l. Arrhythmia inducibility and effective re-
fractory period (ERP) were measured by using single
right atrial extrastimuli after steady-state pacing in
1-ms decrements (15–18). Transmembrane action
potentials were recorded using borosilicate glass
microelectrodes from superfused murine LAs (17),
RMP, action potential duration (APD), upstroke ve-
locity, and activation times were analyzed (15,17,18).
The human atrial cell model of Courtemanche et al.
(19) was used. Pitx2cþ/– deﬁciency was modeled by
reducing IK1 conductance by 25% and doubling IKr
conductance. Simulations were run in strands of 100
atrial cells (cell length 100 mm). The 5 leftmost cells of
the strand were paced (S1) for 2 min at 1,000- and
500-ms basic cycle lengths. Premature stimulation
(S2) was applied to determine the ERP and conduc-
tion velocity as measured from cells 25 to 75. Values
for all other parameters were measured from the
50th cell. For the modeling, post-repolarizationio-Techne (R&D Products). Dr. Fabritz has received
. Dr. Kirchhof has received further research support
vice companies active in atrial ﬁbrillation; and has
and Kirchhof are listed as inventors on a patent
c antiarrhythmic drug therapy of atrial ﬁbrillation.
o the contents of this paper to disclose. Drs. Syeda
2016, accepted July 20, 2016.
TABLE 1 Baseline Characteristics (N¼ 101)*
Age, yrs 59.7  8.4 (40–76)
Male 79
Congestive heart failure 6
Hypertension 34
Age $75 yrs 1
Diabetes 9
Stroke/transient ischemic attack/embolus 10
Vascular disease 10
Female 22
Age $65 yrs 31
CHA2DS2-VASc score
0 60
1 24
$2 17
Previous catheter ablation for AF 20
Type of AF
Paroxysmal 44
Persistent 56
Longstanding persistent 1
AF duration, yrs 6.0 (1–35)
Antiarrhythmic drugs and rate control agents
Quinidine or disopyramide 4
Flecainide or propafenone 33
Amiodarone, dronedarone, or sotalol 41
Beta blockers 53
Verapamil or diltiazem 17
Digoxin 15
Anticoagulant agents (before PVI procedure)
Vitamin K antagonists 89
Antiplatelets 6
Values are mean  SD (range), n, or mean (range). *Left atrial appendages were
collected from these patients with atrial ﬁbrillation (AF).
PVI ¼ pulmonary vein isolation.
TABLE 2 PITX2 mRNA Expression in Left Atrial Appendages From
AF Ablation Patients*
Risk
Alleles 25% IQR Median 75% IQR Mean SEM
No. of
Patients
0 3.22 3.69 5.22 4.04 0.6 3
1 2.96 4.25 6.25 4.54 0.5 13
2 2.65 3.78 4.75 3.94 0.3 22
3 2.74 3.72 4.92 3.83 0.4 17
4 3.00 4.29 5.41 4.39 0.5 10
5 1.96 2.66 4.66 3.10 0.7 4
6 4.95 4.95 4.95 4.95 0.0 1
*This dataset was grouped according to the number of risk single nucleotide polymorphism (SNP)
alleles for AF on chromosome 4q25 (rs2200733, SNP2 rs6838973, rs1448818 [13]). Although
PITX2mRNA is numerically lower in patients with 5 or 6 risk alleles, we did not ﬁnd a PITX2mRNA
gradient according to AF risk.
IQR ¼ interquartile range; LA ¼ left atrium; other abbreviations as in Table 1.
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1883refractoriness (PRR) was calculated as the difference
between APD at –60 mV repolarization and ERP.
LA cell isolation was performed as previously re-
ported (20). Standard INa and IK1 currents were
recorded as previously published (18–20). Back-
ground Kþ (TASK-like) currents sensitive to high Ba2þ
(10 mM) were measured (21–23). Human embryonic
kidney (HEK) 293 cells stably expressing the human
Nav1.5 channel were obtained (SB Ion Channels,
Glasgow, UK).
Ribonucleic acid and complementary deoxy-
ribonucleic acid were synthesized from murine LA,
(SuperScript VILO, Thermo Fisher Scientiﬁc Inc.) to
quantify expression of 20 atrial ion channels and
genes with suspected PITX2-dependent regulation (9)
using custom-designed Taqman low density array
plates (Thermo Fisher Scientiﬁc Inc.). Western
immunoblotting was performed on murine LA tissue
lysates with antibodies detecting TASK-2, Kv1.6, Na/K
ATPase alpha-1, Na/K ATPase alpha-2, Na/Ca
exchanger 1, Serca2a, Nav1.5, or calnexin, using
standard methods.
Optical action potentials and calcium ion (Ca2þ)
transients were recorded in murine LA and analyzed
using custom-made MATLAB algorithms (MathWorks,
Natick, Massachusetts) as previously described (17).
STATISTICAL ANALYSIS. All experiments were per-
formed and analyzed in a blinded fashion. Murine
studies were performed and analyzed blinded to ge-
notype in littermate pairs. Categorical data were
compared using the Fisher exact test. Numerical data
were compared by 2-sided paired parametric Student
t tests (e.g., measurements before and after perfusion
of ﬂecainide or sotalol) and Wilcoxon signed rank
tests. Multiple measurements were assessed by
repeated measures of analysis of variance followed by
correction for multiple comparison (Bonferroni test)
if the overall test was signiﬁcant. Two-sided p < 0.05
were considered signiﬁcant. Box plots depict indi-
vidual measurements (points), mean, and SEM. Sta-
tistics and ﬁgures were created using Prism 5
(GraphPad Software, San Diego, California).
RESULTS
PITX2 mRNA varied markedly in human LAA (Central
Illustration) harvested from AF patients (Table 1) (13),
suggesting that a 50% lowered PITX2 expression de-
ﬁnes a large, potentially clinically relevant group of
AF patients. This did not directly correlate with SNP
haplotype (Table 2), although we found numerically
lower PITX2c levels in patients with 5 risk alleles.
Flecainide suppressed atrial arrhythmias in murine
Pitx2cþ/– hearts. Flecainide abolished induced atrialarrhythmias in hearts with reduced Pitx2c expression
(0 of 17 hearts with atrial arrhythmias) but not in
hearts with normal Pitx2c expression (atrial arrhyth-
mias remained in 3 of 12 hearts) (Figures 1A to 1C).
FIGURE 1 Atrial Arrhythmia Inducibility in Pitx2cþ/– Murine Whole Hearts
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(A) Image and schematic representation of the Langendorff-perfused heart. (B) Atrial arrhythmia inducibility in isolated, beating hearts from
wild-type (WT) and reduced paired like homeodomain 2 messenger ribonucleic acid (Pitx2cþ/–) mice. Flecainide abolished atrial arrhythmia
inducibility in Pitx2cþ/– hearts only. *p < 0.05 ﬂecainide versus baseline. (C) Representative trace of atrial ﬁbrillation (AF) induced during
programmed stimulation at baseline, showing reduced severity of arrhythmias with 1 mmol/l ﬂecainide in Pitx2cþ/– atria. (D) Effects of ﬂecainide
on atrial effective refractory period (ERP) in wild-type and Pitx2cþ/– isolated, beating hearts. Shown is the difference in atrial ERP between
baseline and 1 mmol/l ﬂecainide at 80- to 120-ms paced cycle length following a single extrastimulus (S2) in WT and Pitx2cþ/– isolated, beating
hearts. *p < 0.05 between genotypes across all cycle lengths. (E) Whereas ﬂecainide prolonged ERP in both genotypes, this effect was more
pronounced in Pitx2cþ/– atria. Flecainide caused post-repolarization refractoriness (PRR), the difference between ERP (orange and grey lines)
and APD90 (blue lines), in WT and Pitx2cþ/– atria. Flecainide-induced PRR in Pitx2cþ/– is almost 3 times that of WT atria. *p < 0.05 WT
versus Pitx2cþ/–. #p < 0.05 baseline versus 1 mmol/l ﬂecainide. APD ¼ action potential duration; EG ¼ intracardiac electrogram; EP ¼
electrophysiology; LA ¼ left atrium; LV ¼ left ventricle; MAP ¼ monophasic action potential; RA ¼ right atrium; RV ¼ right ventricle.
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TABLE 3 Effect of Flecainide on Refractoriness and Repolarization in Mouse Hearts
Wild-Type Pitx2cþ/–
Paced CL, ms 120 100 80 120 100 80
Baseline Flecainide Baseline Flecainide Baseline Flecainide Baseline Flecainide Baseline Flecainide Baseline Flecainide
LA ERP, ms
23.5  2.3 (11) 29.8  3.0 (11) 22.2  2.1 (11) 29.6  3.3 (11) 21.9  2.4 (10) 28.7  3.5* (10) 30.5  2.4 (11) 38.5  3.3* (11) 28.0  2.3 (13) 40.2  2.8* (13) 27.5  2.5 (13) 41.2  3.0*† (13)
LA monophasic APD, ms
APD50 10.2  1.3 (8) 14.5  1.7 (8) 10.8  1 (8) 11.9  1.6 (8) 10.4  0.7 (7) 12.0  1.1 (7) 12.4  1.1 (15) 14.4  1.3 (15) 11.5  1.0 (15) 12.4  1.1 (15) 10.6  0.9 (11) 10.3  1.0 (11)
APD70 17.8  2.2 (9) 23  2.1 (9) 18.4  1.6 (9) 18.7  2.2 (9) 18.1  1.2 (8) 18.1  1.9 (8) 18.0  1.6 (15) 19.2  1.8 (15) 16.0  1.4 (13) 16.2  1.4 (13) 14.9  1.0† (10) 13.1  0.7 (10)
APD90 31.3  3.0 (8) 37.4  2.8 (8) 31.5  2.5 (9) 29.9  2.9 (9) 31.0  1.4 (8) 28.4  2.7 (8) 28.3  2.2 (13) 29.9  2.2 (13) 27.4  2.2 (13) 26.6  1.5 (13) 26.8  1.7 (10) 23.1  1.4 (10)
LA transmembrane APD, ms
APD30 4.5  0.1 (30) 5.5  0.3 (22) 4.5  0.1 (30) 5.4  0.3 (22) 4.4  0.1 (30) 5.2  0.3 (22) 4.0  0.1 (31) 4.7  0.2 (24) 3.9  0.1 (31) 4.6  0.2 (24) 3.8  0.1† (31) 4.4  0.2 (24)
APD50 6.7  0.2 (30) 8.2  0.5 (22) 6.6  0.2 (30) 8.0  0.4 (22) 6.4  0.2 (30) 7.8  0.5 (22) 5.9  0.2 (31) 7.1  0.4 (24) 5.7  0.2 (31) 7.0  0.4 (24) 5.6  0.2† (31) 6.7  0.3 (24)
APD70 10.5  0.4 (30) 12.7  0.8 (22) 10.1  0.4 (30) 12.1  0.7 (22) 9.6  0.4 (30) 11.8  0.7 (22) 8.9  0.4 (31) 10.7  0.6 (24) 8.6  0.4 (31) 10.3  0.6 (24) 8.3  0.3† (31) 9.8  0.5 (24)
APD90 20.9  1.0 (30) 23.4  1.5 (22) 19.9  0.9 (30) 22.2  1.4 (22) 18.4  0.8 (30) 21.6  1.3 (22) 17.6  0.9 (31) 20.3  1.1 (24) 16.5  0.8 (31) 19.2  1.0 (24) 15.7  0.8† (31) 17.9  0.9 (24)
LA optical APD, ms
APD30 6.1  0.3 (10) 7.3  0.6 (6) 6.4  0.8 (10) 5.9  1.0 (6) 6.1  0.4 (10) 6.9  1.3 (6) 4.9  0.4 (10) 7.7  0.9 (8) 4.6  0.3 (10) 5.4  0.7 (8) 4.3  0.4† (10) 5.7  0.7 (8)
APD50 8.5  0.6 (10) 10.7  1.2 (6) 8.9  1.1 (10) 8.5  1.2 (6) 8.3  0.7 (10) 10.3  1.8 (6) 6.9  0.4 (10) 10.0  1.0 (8) 6.6  0.4 (10) 8.1  0.9 (8) 6.1  0.4† (10) 8.0  0.9 (8)
APD70 11.7  1.2 (10) 15.0  2.1 (6) 12.5  1.5 (10) 12.8  1.7 (6) 11.5  1.1 (10) 14.4  2.5 (6) 9.4  0.0 (10) 13.3  1.2 (8) 9.4  0.6 (10) 11.6  1.5 (8) 9.1  0.5† (10) 11.2  1.2 (8)
Values are mean  SEM (number of atria). *p < 0.05 vs. baseline. †p < 0.05 vs. wild-type.
APD ¼ action potential duration; CL ¼ cycle length; ERP ¼ effective refractory period; Pitx2cþ/– ¼ PITX2 deﬁcient; other abbreviations as in Tables 1 and 2.
TABLE 4 Electrophysiological Effects of Sotalol
Wild-Type Pitx2cþ/–
Paced CL, ms 120 100 120 100
Baseline Sotalol Baseline Sotalol Baseline Sotalol Baseline Sotalol
LA ERP, ms
38.7  7.8 (7) 33.9  6.3 (7) 32.2  6.1 (6) 29.2  5.3 (6) 39.3  4.0 (4) 26.8  3.5 (4) 37.0  5.7 (4) 24.0  3.7 (4)
LA APD, ms
APD50 11.5  1.2 (9) 13.4  1.2 (9) 10.9  2.0 (7) 12.2  1.3 (7) 10.8  1.1 (7) 11.2  1.0 (7) 8.3  0.9 (4) 11.1  1.7 (4)
APD70 17.6  2.2 (9) 20.0  1.9 (9) 16.0  1.3 (7) 18.2  2.3 (7) 16.5  1.6 (7) 17.3  1.2 (7) 13.0  1.5 (4) 17.0  1.9 (4)
APD90 30.7  3.2 (9) 33.5  2.7 (9) 29.0  1.9 (7) 30.9  3.2 (7) 29.7  2.7 (7) 31.2  2.0 (7) 23.8  2.8 (4) 29.6  2.9 (4)
Values are mean  SEM (number of atria).
Abbreviations as in Tables 2 and 3.
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FIGURE 2 Resting Membrane Potential and Maximum Upstroke Velocity
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(A) Schematic representation of sharp microelectrode electrode recordings from the superfused whole LA. (B) Resting membrane potential
(RMP) in WT and Pitx2cþ/– LA at baseline and with 1 mmol/l ﬂecainide. Pitx2cþ/– LA have depolarized RMP. The difference between WT and
Pitx2cþ/– is exaggerated with ﬂecainide. *p < 0.05; ***p < 0.001 across all cycle lengths. (C) Flecainide unmasked a lower maximum upstroke
velocity (dV/dtmax) in Pitx2c
þ/– LA compared to WT. **p < 0.01 versus WT. Abbreviations as in Figure 1.
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1886Flecainide prolonged ERPs and refractoriness
beyond the end of repolarization (PRR) calculated as
the difference between ERP and APD90 (ms). Flecai-
nide prolonged PRR more in hearts with reduced
Pitx2c expression (Figures 1D and 1E, Table 3).
PITX2cþ/– hearts had shorter atrial action potentials(8). Flecainide abolished APD differences bet-
ween Pitx2cþ/– and wild-type LA by prolonging
early repolarization (APD30, APD50, and APD70)
(Table 3). Murine atrial PITX2 expression did not
modulate the effects of sotalol on atrial APD or ERP
(Table 4).
FIGURE 3 Modeling of the Electrophysiological Consequences of Pitx2c Deﬁciency
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(A) Propagated action potentials (top) simulated with the Courtemanche–Ramirez–Nattel model modiﬁed to reﬂect the more positive RMP of
murine Pitx2cþ/– atria and the effect of 60% sodium current (INa) block at pacing cycle lengths of 500 and 1,000 ms, with 2-min pre-pacing,
and corresponding time courses of the product of the 2 inactivation gates h and j of INa (bottom), reﬂecting INa availability. (B) Reduced sodium
conductance (gNa) increased post-repolarization refractoriness (PRR) in the reference model and the Pitx2c deﬁciency model. After reducing
gNa, PRR was greater in the Pitx2c deﬁciency model than in the reference model (grey lines). Lines denote APD60 (blue) and ERP (orange: with
100% gNa; grey: with 40% gNa). Abbreviations as in Figures 1 and 2.
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1887RMP was slightly depolarized in LA murine cells
with reduced Pitx2c expression (range of mean de-
polarization 1.2 to 2.4 mV over 5 cycle lengths; all
p < 0.05) (Figures 2A and 2B). Atrial Pitx2c levels did
not signiﬁcantly affect dV/dtmax (100-ms paced cycle
length: wild-type: 104.4  4.3 V/s; Pitx2cþ/–:
93.7  4.5 V/s) (Figure 2C). Flecainide did not modify
atrial RMP (Figure 2B) but reduced action potential
amplitude consistent with its Na-channel blocking
effect, speciﬁcally at 100-ms cycle length: wild-
type baseline: 77.5  1.2 mV (n ¼ 30); wild-type
ﬂecainide: 71.3  1.2 mV (n ¼ 31); Pitx2cþ/– base-
line: 73.4  1.3 mV (n ¼ 22); and Pitx2cþ/– ﬂecainide:
65.1  1.45 mV (n ¼ 24).
Because the Courtemanche–Ramirez–Nattel model
does not incorporate background Kþ currents (19), we
simulated a depolarized RMP in this model by a 25%reduction in IK1. This reduced the RMP at 500-ms
paced cycle length by 2 mV from 79.9 mV (“normal
PITX2”) to –77.9 mV (“low PITX2”). Na channels
recovered from inactivation more slowly upon partial
INa block (50% or 60%) (Figure 3A). Furthermore,
PRR was enhanced in the PITX2 deﬁciency model
(Figure 3B and Table 5). Inhibition of INa reduced up-
stroke velocity (dV/dtmax) and conduction velocity in
both models, and reproduced the prolongation of PRR
(Figure 3B).
Kcna6 and Kcnk5mRNA expression were reduced in
Pitx2cþ/– murine LA (Figure 4A, Online Table 1),
whereas mRNA concentrations of 20 other ion chan-
nels or related genes were not altered. Kv1.6 protein
concentration was unaltered, whereas TASK-2 protein
concentration was reduced in murine atria with
reduced Pitx2c expression (Figure 4B). Nav1.5 mRNA
TABLE 5 Electrophysiological Effects of Reduced Sodium
Conductance in a Human Atrial Model
Wild-Type Model
Pitx2c Deﬁciency
Model
Paced CL, ms 500 1,000 500 1,000
RMP, mV
gNa, %
100 -79.92 -81.28 -77.90 -79.61
50 -79.60 -81.12 -77.33 -79.37
40 -79.43 -81.01 -76.99 -79.23
APD at repolarization to -60 mV, ms
gNa, %
100 217 253 206 226
50 239 266 233 239
40 248 273 245 245
ERP, ms
gNa, %
100 266 301 261 280
50 308 335 316 320
40 327 352 342 339
PRR, ms
gNa, %
100 49 48 55 54
50 69 69 83 81
40 79 79 97 94
Conduction velocity, cm/s
gNa, %
100 49.5 50.0 50.3 50.5
50 36.9 37.0 37.5 37.5
40 32.9 32.7 33.0 33.1
gNa ¼ reduced sodium conductance; PRR ¼ post-repolarization refractoriness;
RMP ¼ resting membrane potential; other abbreviations as in Table 3.
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1888and protein expression were not changed (Figures 4A
and 4B).
Atrial Pitx2c expression did not modify peak Naþ
currents (INa) recorded from isolated murine car-
diomyocytes at holding potentials ranging from –100
to –65 mV (Figures 5A to 5C). Peak INa was reduced at
more depolarized holding potentials (Figure 5). Fle-
cainide inhibited INa better at more positive holding
potentials (inhibition at –70 mV: 68  5%; inhibition
at –65 mV: 75  5%; n ¼ 86 cells from n ¼ 17 atria) in
cells from murine atria with normal or reduced Pitx2c
expression, suggesting that the greater efﬁciency of
ﬂecainide in atria with reduced Pitx2c expression is
secondary to RMP depolarization (Figure 5C). Consis-
tent with this, ﬂecainide inhibited human Nav1.5
channels expressed in HEK cells more potently at
more depolarized test potentials (–65 to –75 mV)
(Figures 5D and 5E).
Background Kþ currents, which include TASK cur-
rents, were reduced in Pitx2cþ/– murine atria, whereas
IK1 did not differ between genotypes (Figure 6).Reduced Pitx2c expression did not alter atrial
conduction velocities or activation patterns (Online
Figures 1A to 1C, Table 6), consistent with pub-
lished data (8). We found that 1 mmol/l ﬂecainide
decreased atrial conduction velocities without dif-
ferences between wild-type and Pitx2cþ/– mice
(Online Figures 1B and 1C). Calcium transient relax-
ation times at 50% relaxation were not different
between wild-type and Pitx2cþ/– (Online Figures 1D
and 1E). Flecainide 1 mmol/l shortened 50% Ca2þ
relaxation times by approximately 10% and
decreased Ca2þ transient amplitude by approxi-
mately 50% in murine atria with normal and reduced
Pitx2c expression (Online Figures 1E and 1F). Addi-
tionally, expression of the Na/Ca exchanger Serca2a
and Na/K ATPase alpha-1 and alpha-2 subunit pro-
tein did not differ between wild-type and Pitx2cþ/–
atria (Online Figure 2).
DISCUSSION
This study demonstrated that LA PITX2 mRNA con-
centrations vary in patients with AF requiring rhythm
control therapy (Central Illustration). Furthermore,
ﬂecainide increases PRR and suppresses arrhythmias
more effectively in atria with halved Pitx2c expres-
sion, mediated by a more depolarized RMP (Central
Illustration). Drug-induced PRR is thought to pre-
vent arrhythmias, as reactivation can then occur only
after full recovery of excitability, avoiding slow
propagation during the vulnerable period (16,24,25).
We found similar effects in cells expressing human Na
channels and in the Courtemanche–Ramirez–Nattel
model of human atrial action potentials.
Thus, this study highlighted modulation of the
atrial RMP by PITX2, possibly mediated by back-
ground currents such as TASK-2, as a target for AAD
therapy, including atrial-selective therapy. Further-
more, the results suggested that markers for atrial
PITX2 expression may identify AF patients who
beneﬁt from Na-channel blocker therapy (Central
Illustration).
Low atrial PITX2 expression was identiﬁed as an
important determinant of the antiarrhythmic effects
of Na channel blockers. Low LA Pitx2c mRNA depo-
larized atrial RMP (Figure 2), consistent with a previ-
ous report (11). A depolarized RMP increased
ﬂecainide-induced PRR (Figure 1) (26–30). The
conduction-slowing effect of ﬂecainide was not
modulated by reduced atrial Pitx2c (Online Figure 1),
an important surrogate for drug safety. Both the
modeling experiments (Figure 3) and the experiments
in HEK cells expressing human Na channels (Figure 5)
FIGURE 4 mRNA and Protein Expression in Murine LA
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(A) Relative quantity (RQ) of messenger ribonucleic acid (mRNA) of selected ion channels in LA from Pitx2cþ/– and WT mice. Expression levels
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1889conﬁrmed that small changes in RMP can markedly
modulate Na-channel inhibition.
RESTING MEMBRANE POTENTIAL. Open-state Na-
channel blockers such as ﬂecainide and propafenone
bind preferentially to Na channels integrated in
membranes with slightly depolarized resting
potentials, where more channels are in the open or
inactivated state (31,32). Our data can be interpreted as
suggesting that AAD combinations that include a Na-
channel blocker with a membrane potential modi-
fying substance, such as amiodarone (16,33) or
the combination of dronedarone and ranolazine
(29,34,35), may have synergistic antiarrhythmic
effects because they modulate atrial RMP and thereby
enhance the effect of Na-channel blockade. Further
studies of such drug combinations and the relation-
ship between their effectiveness and the patient’s
atrial PITX2mRNA levels are warranted. Our data also
suggested that such combined effects may be
of special relevance in patients who have a depolar-
ized RMP, such as secondary to low LA PITX2. Because
PITX2 expression is conﬁned to the LA in the heart,
AAD therapy that leverages modiﬁcations in RMP may
achieve “atrial-speciﬁc” AAD therapy.RMP is maintained by an intricate balance of
different transmembrane currents and is closely
related to the potassium equilibrium potential. We
identiﬁed that PITX2 modiﬁes expression of the
genes encoding Kv1.6 and TASK-2 (Figure 4). Com-
plete deletion of PITX2 regulates other potassium and
Na channels such as Kcnj2 (8,36), which alter the
RMP, but these were not responsible for the depo-
larized RMP observed in our study. Two-pore domain
potassium channels, such as TASK-2, contribute to
RMP in various cells, including skeletal and cardiac
muscle (37,38). To date, an altered function of the
TASK-1 channel and of IK1 has been implicated in
atrial remodeling and AF (39,40). This study demon-
strated that TASK-2 is expressed in atrial myocardium
(Figure 4B), suggesting that a reduced function of
TASK-2 could depolarize RMP (Figures 1 and 5) (8,11),
analogous to the effect of TASK-2 in neuronal and
cartilage tissue (41,42).
DEVELOPING CLINICAL MARKERS FOR PATIENTS
WITH DEPOLARIZED RMP. It will be challenging to
directly assess LA RMP in AF patients, but our data
suggested that differences in atrial RMP could explain
the effectiveness of Na-channel blockers in carriers of
FIGURE 5 Effect of Membrane Potential on Sodium-Channel Inhibition
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(A) Schematic representation of patch clamp experiments carried out in isolated atrial cardiomyocytes. Human embryonic kidney (HEK) cells
were patch clamped using the same setup. (B) Representative traces showing INa measured by patch clamping in isolated atrial cardiomyocytes,
at baseline and with ﬂecainide, at increasing holding potentials (–100 to –65 mV). (C) Reduction in peak INa was enhanced with increased
holding potentials, irrespective of cardiomyocyte origin. (D) Representative traces showing INa in Nav1.5-transfected HEK cells at baseline and
with ﬂecainide at increasing holding potentials (–100 to –65 mV). (E) Reduction in peak INa with ﬂecainide in Nav1.5-transfected HEK cells was
enhanced with increased holding potentials. The greatest difference in percent reduction was between –70 and –65 mV. Abbreviations as in
Figures 1 to 3.
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1890common gene variants on chromosome 4q25 (43),
although LA PITX2 levels are modulated by factors
other than SNP status (Table 2) (44). It seems desir-
able to develop and validate drivers that modify RMP
and clinical markers for patients prone to a depolar-
ized atrial RMP to select appropriate AADs for indi-
vidual patients in the future, thus enabling
personalized AAD selection (6,45).
STUDY LIMITATIONS. This study provided robust
evidence that LA PITX2 expression varies in AFpatients and that reduced PITX2c expression en-
hances the antiarrhythmic effects of Na-channel
blockers by modulating atrial RMP. The study was
partly motivated by the assumption that gene vari-
ants on chromosome 4q25 modify PITX2 expression,
an assumption that has not been deﬁnitively proven
(9,11,44,46). Our analysis (Table 2) and that of others
indicate that SNP status does not always correlate
with PITX2 levels (47,48). Our ﬁndings are relevant to
AAD therapy even if the presumed link between
PITX2 expression and genetic variants on
FIGURE 6 Currents Responsible for RMP
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than WT cardiomyocytes. *p < 0.05. Abbreviations as in Figures 1 to 3.
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1891chromosome 4q25 proves elusive. The mechanisms
by which reduced PITX2 mRNA concentrations
shorten the LA action potential at high heart rates
remain to be fully elucidated (8,20). Validating our
ﬁndings in patients is desirable but will be chal-
lenging because access to fresh LA cardiomyocytes
and LA tissue is limited.TABLE 6 Electrical Activation Time and Conduction Velocity in Isolat
Wild-Type
Paced CL, ms 1,000 300 120
Activation time (isolated
left atrium), ms
6  0.3 (22) 6  0.3 (22) 9  0.5 (22) 12
Conduction velocity
(optical mapping), cm/s
— 30  1.8 (8) 25  2.4 (8) 25
Values are mean  SEM (number of atria).
— ¼ not applicable; other abbreviations as in Table 3.Due to the novelty of our ﬁndings, we could not
perform a priori power calculations for our mecha-
nistic experiments, and we analyzed several func-
tional parameters to identify potential mechanisms
conveying the antiarrhythmic effects of ﬂecainide in
atria with low Pitx2c concentrations. Our ﬁndings
thus require independent validation.ed Atria in the Presence of Flecainide (1 mmol/l)
Pitx2cþ/–
100 80 1,000 300 120 100 80
 1.0 (22) 16  1.4 (22) 6  0.2 (24) 7  0.3 (24) 12  0.9 (24) 13  0.9 (24) 18  1.2 (24)
 1.9 (8) 23  1.9 (8) — 29  1.5 (8) 26  1.6 (8) 25  1.6 (8) 23  1.6 (8)
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
PITX2, a transcription factor linked to left–right
asymmetry in the chest during development, modu-
lates the expression of LA ion channels maintaining
the RMP and modulates the antiarrhythmic effects of
Na-channel blockers.
TRANSLATIONAL OUTLOOK: Clinical studies are
needed to assess whether reduced PITX2 expression
identiﬁes patients with AF who respond favorably to
Na-channel blocking drugs.
CENTRAL ILLUSTRATION PITX2 Deﬁciency Potentiates Flecainide’s Antiarrhythmic Effects
Syeda, F. et al. J Am Coll Cardiol. 2016;68(17):1881–94.
Paired like homeodomain 2 (PITX2) might play an important role in regulating gene expression and electrical function of the left atrium. (Left) Pitx2 messenger
ribonucleic acid (mRNA) levels are variable in left atrial appendages of patients undergoing thoracoscopic atrial ﬁbrillation (AF) ablation therapy. The differentiation
between “low” (orange) and “high” (blue) PITX2 levels is somewhat arbitrary. (Right) A low left atrial PITX2c mRNA expression slightly depolarizes left atrial resting
membrane potential (RMP). A depolarized RMP, in turn, enhances the antiarrhythmic effect of sodium-channel blockers such as ﬂecainide. PRR ¼ post-repolarization
refractoriness.
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1892CONCLUSIONS
This study shows that low LA PITX2 mRNA levels
increase atrial RMP and thereby increase the effec-
tiveness of ﬂecainide (Central Illustration). This
ﬁnding calls for appropriately designed clinical
studies to assess whether AF patients with low atrial
PITX2 levels respond favorably to Na-channel
blockade. Further studies exploring the relevance of
TASK channels to atrial RMP also are warranted.
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